Prognostic Value of FDG-PET Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2015 Mar 12

PMID 25758829

Citations 52

Authors

Craig S Sauter

Matthew J Matasar

Jessica Meikle

Heiko Schoder

Gary A Ulaner

Jocelyn C Migliacci

Patrick Hilden

Sean M Devlin

Andrew D Zelenetz

Craig H Moskowitz

Affiliations

Soon will be listed here.

Abstract

High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using (18)F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.

Citing Articles

Using Deauville Scoring to Guide Consolidative Radiotherapy in Diffuse Large B-Cell Lymphoma.

Yau C, Low C, Ong W, Khoo L, Hoe J, Tan Y Cancers (Basel). 2024; 16(19).

PMID: 39409931 PMC: 11475697. DOI: 10.3390/cancers16193311.

Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy.

Moyo T, Vaidya R Front Oncol. 2024; 14:1397186.

PMID: 39211553 PMC: 11357917. DOI: 10.3389/fonc.2024.1397186.

Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy.

Yagi Y, Kanemasa Y, Sasaki Y, Goto S, Yamamura Y, Masuda Y J Clin Exp Hematop. 2024; 64(2):107-118.

PMID: 38925972 PMC: 11303961. DOI: 10.3960/jslrt.24009.

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is There Still a Role for Autologous Stem Cell Transplantation in the CAR T-Cell Era?.

Strussmann T, Marks R, Wasch R Cancers (Basel). 2024; 16(11).

PMID: 38893108 PMC: 11171011. DOI: 10.3390/cancers16111987.

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options.

Garcia-Sancho A, Cabero A, Gutierrez N J Clin Med. 2024; 13(1).

PMID: 38202077 PMC: 10779497. DOI: 10.3390/jcm13010070.

References

Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333(23):1540-5. DOI: 10.1056/NEJM199512073332305. View

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

Hoppe B, Moskowitz C, Filippa D, Moskowitz C, Kewalramani T, Zelenetz A . Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. J Clin Oncol. 2008; 26(11):1858-64. DOI: 10.1200/JCO.2007.15.4773. View

Derenzini E, Musuraca G, Fanti S, Stefoni V, Tani M, Alinari L . Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer. 2008; 113(9):2496-503. DOI: 10.1002/cncr.23861. View

Hoppe B, Moskowitz C, Zhang Z, Maragulia J, Rice R, Reiner A . The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2009; 43(12):941-8. DOI: 10.1038/bmt.2008.408. View

Meignan M, Gallamini A, Haioun C . Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009; 50(8):1257-60. DOI: 10.1080/10428190903040048. View

Dickinson M, Hoyt R, Roberts A, Grigg A, Seymour J, Prince H . Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol. 2010; 150(1):39-45. DOI: 10.1111/j.1365-2141.2010.08162.x. View

Roland V, Bodet-Milin C, Moreau A, Gastinne T, Mahe B, Dubruille V . Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplant. 2010; 46(3):393-9. DOI: 10.1038/bmt.2010.130. View

Moskowitz C . Interim PET-CT in the management of diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2012; 2012:397-401. DOI: 10.1182/asheducation-2012.1.397. View

10.

Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch D, Trneny M . Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012; 30(36):4462-9. PMC: 3646314. DOI: 10.1200/JCO.2012.41.9416. View

11.

Armand P, Welch S, Kim H, LaCasce A, Jacobsen E, Davids M . Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013; 160(5):608-17. DOI: 10.1111/bjh.12176. View

12.

Villa D, Crump M, Panzarella T, Savage K, Toze C, Stewart D . Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol. 2013; 31(9):1164-71. DOI: 10.1200/JCO.2012.44.0693. View

13.

Vose J, Carter S, Burns L, Ayala E, Press O, Moskowitz C . Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the.... J Clin Oncol. 2013; 31(13):1662-8. PMC: 3635682. DOI: 10.1200/JCO.2012.45.9453. View

14.

Armand P, Nagler A, Weller E, Devine S, Avigan D, Chen Y . Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013; 31(33):4199-206. PMC: 4878008. DOI: 10.1200/JCO.2012.48.3685. View

15.

Sauter C, Lechner L, Scordo M, Zheng J, Devlin S, Fleming S . Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(6):881-4. PMC: 5716350. DOI: 10.1016/j.bbmt.2014.02.009. View

16.

Barrington S, George Mikhaeel N, Kostakoglu L, Meignan M, Hutchings M, Mueller S . Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014; 32(27):3048-58. PMC: 5015423. DOI: 10.1200/JCO.2013.53.5229. View

17.

Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244. DOI: 10.1200/JCO.1999.17.4.1244. View

18.

Schot B, Zijlstra J, Sluiter W, van Imhoff G, Pruim J, Vaalburg W . Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2006; 109(2):486-91. DOI: 10.1182/blood-2005-11-006957. View